Protinhi Therapeutics

We have discovered and patented a novel class of Geminoid protease inhibitors that target membrane bound proteases, such as viral proteases and metalloproteases. Our Geminoid synthesis platform combines a variable element for optimal selectivity and a variable element for localised or targeted delivery to the disease area. Our aim is to develop high quality candidate drugs to preclinical or early clinical stage and subsequently out-license or co-develop these with pharma or biotech partners.

Our initial focus, based on an existing collaboration with academia, is on inhibitors of membrane bound proteases involved in viral disease, in particular on Dengue. Further, Protinhi will target chronic (lung) disease such as the orphan disease cystic fibrosis (CF). The Geminoid synthesis and test platform provides us with a balanced risk as we can target multiple proteases.

Protinhi Therapeutics

Transistorweg 5 (Building M)

6534 AT Nijmegen

The Netherlands


More companies in this area

DFE Pharma

DFE Pharma develops, produces and supplies excipients for use in oral solid dose and dry powder inhalation,


Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.


TropIQ Health Sciences offers laboratory screening services for the discovery and development of drugs against malaria.

Okklo Life Sciences

Okklo Life Sciences is a privately held biopharmaceutical company developing novel therapeutic solutions using cyclodextrin-based technologies, with a focus on neglected and orphan diseases.


Epigenetics is an exciting area of molecular biology that identifies key changes in gene activity that do not involve changes to the underlying genetic code.


Avivia is an independent specialized pharmaceutical development company engaged in drug repositioning, repurposing and reformulation.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!